XML 81 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitment & Contingencies - In-License Agreement for Lotilaner (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended 31 Months Ended
Dec. 31, 2022
Sep. 30, 2020
Jan. 31, 2019
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Mar. 31, 2023
Intangible Assets, Milestone Payment              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Useful life       10 years      
License agreement | Elanco              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Upfront payment received     $ 1.0        
Future cash payments       $ 2.0      
Maximum milestone payments       75.0      
Royalty expense       1.2      
Common stock issued for license agreement (shares)   222,460          
Common stock issued for license agreement, value   $ 3.1          
Common stock issued for license agreement, share price (usd per share)   $ 14.0003          
License agreement | Clinical milestones | Elanco              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contractual milestone payment $ 0.5       $ 1.0   $ 4.0
Maximum milestone payments       4.0      
License agreement | Commercial and sales milestones              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Maximum milestone payments       $ 77.0      
License agreement | Commercial and sales milestones | Elanco              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contractual milestone payment           $ 4.0